iBio announces rights grant for anthrax-plague combination vaccine

NEWARK, Del. A biotech company has granted rights to its vaccine-development platform to a government-funded effort to create a vaccine to protect against anthrax and plague.

The company, iBio, announced Wednesday the grant of rights to the iBioLaunch platform in support of the $5.3 million project, managed by the Fraunhofer USA Center for Molecular Biology.

“We are confident in our ability to deliver on the objective of this contract,” CMB executive director Vidadi Yusibov said. “We expect to demonstrate the safety and efficacy of a one-shot vaccine in animal tests in preparation for clinical development.”